AEMD (Aethlon) Short-Term Debt to Capital

Aethlon Medical (AEMD) develops unique filters for clearing blood of cancer particles and viruses, protected by patents and FDA status. This price chart, serving as confirmation of the market valuation, reflects the trend at a value of 0.07. The business aims to implement its systems in intensive care units; however, slow certification of new devices is hindering scaling and increasing operating expenses for the maintenance of research centers.

By developing ESG-oriented blood filtration systems, Aethlon Medical (AEMD) balances bioethical standards with financial sustainability, as reflected in the short-term debt-to-equity chart on GURU.Markets, which measures liabilities due within one year relative to equity to assess default risks amid high interest rates, where a decrease in the metric confirms the reliability of the financing structure but may indicate a slowdown in business expansion.